| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Schedule 13D · 1 security · may seek to influence control | ||||||
|
ALX Oncology Holdings Inc.
13D/A
ALXO · 00166B105
|
10.0% |
10/16/2026
Event 10/14/2026
|
||||
| venBio Global Strategic Fund, L.P. | 3.3% | |||||
| venBio Global Strategic Fund II L.P. | 6.5% | |||||
| venBio Global Strategic GP, L.P. | 3.3% | |||||
| venBio Global Strategic GP II, L.P. | 6.5% | |||||
| venBio Global Strategic GP, Ltd. | 3.3% | |||||
| venBio Global Strategic GP II, Ltd. | 6.5% | |||||
| Goodman Corey S | 10.0% | |||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.